



NZX/ASX Announcement

11 August 2026

TruScreen accelerates African expansion to Rwanda, Nigeria, Ghana, and Côte d'Ivoire

- **Zerocancer Professional Consult Limited (ZPC)** appointed as distributor for Nigeria, Ghana, and Côte d'Ivoire
- **Biotech Medical Supply Ltd (BMS)** appointed as distributor for Rwanda
- The appointments accelerate TruScreen's strategy for African expansion with collaborations with global and local NGO.
- The African expansion anticipates grant outcomes for projects in 8 African nations - Zimbabwe, South Africa, Eswatini, Rwanda, Nigeria, Ghana, Côte d'Ivoire, Kenya – a screening market of up to 132 million women of screening age⁴
- Gap to WHO's 70% cervical cancer screening target remains largest in Africa, with increasing urgency as WHO's 2030 deadline looms

TruScreen Group Limited (NZX/ASX: TRU), ("TruScreen" or "the Company"), a global leader in AI-enabled cervical cancer screening, is pleased to announce that distributors are appointed for Nigeria, Ghana, Cote D'Ivoire and Rwanda – launching the Company's African expansion and supporting government initiatives to meet World Health Organisation screening targets through public screening programs.

Nigeria, Ghana and Côte d'Ivoire (Ivory Coast)

83 million women of screening age, of which Nigeria makes up 64 million.⁴

Zerocancer Professional Consult Limited (ZPC) offer cancer prevention and treatment services and have offices in Lagos, Enugu and other major cities. ZPC brings to TruScreen's African expansion strategy its internal commercial team and an established network of sub-distributors across Nigeria and West Africa, with strong government relationships.

Nigerian product regulatory approval is expected to take 3-6 months, and preparations are underway for a 300-patient clinical evaluation. The data collected from the evaluation will support the application for TruScreen's inclusion in the Nigerian national screening guideline and government screening programs.



In addition to the two major African public screening projects pending UNITAID grant approvals in November 2026, TruScreen is also the chosen screening technology for two Nigeria specific grant applications, submitted by Dr Ayokunle Olumodeji from Lagos State University Teaching Hospital (LASUTH) and Lagos State University College of Medicine (LASUCOM) and supported by the American Association for Cancer Research.

These grant applications are:

1. Gates Foundation's Grand Challenges: Innovations in Cost-Disruptive Tools for Diagnosis and Screening (OPP12345) program - announced 6 May 2026.
2. Beginning Investigator Grant for Catalytic Research (BIG Cat).

Nigeria, Ghana and Cote Côte d'Ivoire are committed to meeting the WHO 70% screening target by 2030 and of the need to accelerate their screening programs to achieve this. In Nigeria as few as 5% of women aged 30–49 years¹ were screened- a long way from meeting the WHO 70% target. In Ghana, only 4.3% of women aged 30–49 years were screened for cervical cancer and in Côte d'Ivoire are 4.4% of women aged 25–49 screened (2021)³.

Rwanda

4.3 million women of screening age.⁴

Biotech Medical Supply Ltd (BMS) focuses on women's health, oncology, and preventive screening. BMS has participated in cervical cancer screening programs for government-led and NGO-supported initiatives and has 25 active sales representatives covering public and private healthcare facilities across Rwanda. BMS have strong relationships with government, NGOs, institutions, Key Opinion Leaders (KOLs) and healthcare providers.

BMS has introduced the TruScreen technology to the Minister of Health and government officials at a recent health conference, and local Key Opinion Leaders (KOLs) and NGOs.

Product registration is in place, and three major government hospitals have completed a pilot study with positive results.

Rwanda is one of Africa's leaders in cervical cancer elimination with estimates of 30% of eligible women being screened by October 2025 – with a further 40% to be screened to achieve the WHO 70% target by 2030.



TruScreen's African Strategy

These distributor appointments further accelerate TruScreen's African strategic expansion.

Together with the UNITAID, Gates Foundation and Clinton Health Access Initiative grant applications submitted in early 2026, TruScreen is growing its distribution network to potentially provide screening services in Zimbabwe, South Africa, Eswatini, Rwanda, Nigeria, Ghana, Côte d'Ivoire and Kenya by 2027, in collaboration with global and local NGOs, including:

- National AIDS Council (NAC), Zimbabwe
- PATH - Global technical partner (Program for Appropriate Technology in Health)
- Solina Centre for International Development and Research (SCIDaR)
- RedAid Nigeria
- Baylor College of Medicine Children's Foundation Eswatini
- Nigeria's Lagos State University Teaching Hospital (LASUTH)
- Lagos State University College of Medicine (LASUCOM)
- University of Nigeria Teaching Hospital

CEO Martin Dillon comments:

"The screening requirements and market opportunities in Africa is huge. TruScreen technology is well suited and positioned to support cervical cancer prevention initiatives in countries where laboratory infrastructure, pathology services and capacity remain insufficient, cervical cancer incidence and mortality is highest, and where the gap to meet the 70% WHO screening target is greatest."

This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:

Martin Dillon
Chief Executive Officer
martindillon@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

¹ Olubodun T, Luoga P, Adam J (2026) [Prevalence and determinants of cervical cancer screening among women aged 30–49 years in Nigeria: A population-based cross-sectional study](#). PLOS Glob

² WHO Integrated African Health Observatory (IAHO) [2023 STEPs Survey findings](#)

³ Public Health 6(6): e0006668. <https://doi.org/10.1371/journal.pgph.0006668>
[Cervical Cancer Screening Cascade in Côte d'Ivoire: A Decade of Real-World Program Evaluation According to HIV Status](#), Simon Boni, David Goore, Mesmin Adie, Franck Gnahatin, Denise Kpebo, Apollinaire Horo, Innocent Adoubi, Antoine Jaquet, JCO Global Oncology 2026 12:4

⁴ Female population ages 15-64, Source: World Population Prospects, United Nations Population Division, World Bank



About TruScreen

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand and Australian listed company with a real-time, AI-enabled cervical cancer screening technology designed to detect pre-cancerous and cancerous changes of the cervix.

The TruScreen device is registered for use in multiple markets and has been used to screen more than 1,000,000 women worldwide.

TruScreen's technology is designed to support cervical cancer screening in settings where access to laboratory infrastructure and specialist pathology services may be limited, making it well suited to emerging markets and public screening initiatives.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

In addition to the TruScreen Ultra cervical cancer screening device, TruScreen has an MOU with Hangzhou Dalton Biosciences Ltd to commercialise their premium hrHPV DNA products in all countries other than the United States and Canada.

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

Glossary:



Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is sent to a laboratory for a pathologist to examine under a microscope. <https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/pap-test>

LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix, onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be done at the same time, such as the human papillomavirus (HPV) test <https://www.cancer.net/cancer-types/cervical-cancer/diagnosis>

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be done on a sample of cells which a person can collect on their own. <https://www.cancer.net/cancer-types/cervical-cancer/screening-and-prevention>

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence or absence of a condition. If individuals who have the condition are considered "positive" and those who don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives and specificity is a measure of how well a test can identify true negatives:

- **Sensitivity** (true positive rate) is the probability of a positive test result, [conditioned](#) on the individual truly being positive.
- **Specificity** (true negative rate) is the probability of a negative test result, conditioned on the individual truly being negative ([Sensitivity and specificity – Wikipedia](#)).

For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia, please see useful links:

New Zealand: [National Cervical Screening Programme | National Screening Unit \(nsu.govt.nz\)](#)

Australia: [Cervical cancer | Causes, Symptoms & Treatments | Cancer Council](#)